bupernorphine (buprenex® subutex® suboxone®) is used to treat which substance use disorder
opioid addiction
title: Buprenorphine text: Buprenorphine Buprenorphine, sold under the brand name Subutex, among others, is an opioid used to treat opioid addiction, acute pain, and chronic pain. It can be used under the tongue, by injection, as a skin patch, or as an implant. For opioid addiction it is typically only started when withdrawal symptoms have begun and for the first two days of treatment under direct observation of a health care provider. For longer term treatment of addiction a combination formulation of buprenorphine/naloxone is recommended to prevent misuse by injection. Maximum pain relief is generally within an hour with effects up to 24 title: Buprenorphine text: Union, Subutex and Suboxone, buprenorphine's high-dose sublingual tablet preparations, were approved for opioid addiction treatment in September 2006. In the Netherlands, buprenorphine is a List II drug of the Opium Law, though special rules and guidelines apply to its prescription and dispensation. Buprenorphine is available under the trade names Cizdol, Suboxone, Subutex (typically used for opioid addiction), Zubsolv, Bunavail, Sublocade, Probuphine, Temgesic (sublingual tablets for moderate to severe pain), Buprenex (solutions for injection often used for acute pain in primary-care settings), Norspan and Butrans (transdermal preparations used for chronic pain). Buprenorphine has been introduced in most European countries as a title: Buprenorphine text: treatment of addiction a combination formulation of buprenorphine/naloxone is usually recommended. A once a month injection, sold under the brandname Sublocade, has been approved in the United States and it should be available in 2018. Both buprenorphine and methadone are medications used for detoxification, short- and long-term opioid replacement therapy. Effectiveness of buprenorphine and methadone appear similar, with similar side effects. A transdermal patch is available for the treatment of chronic pain. These patches are not indicated for use in acute pain, pain that is expected to last only for a short period of time, or pain after surgery, nor title: Buprenorphine text: injection to treat severe pain, with a sublingual formulation released in 1982. In the United States, buprenorphine (Subutex) and buprenorphine with naloxone (Suboxone) were approved for opioid addiction by the United States Food and Drug Administration in October 2002. The FDA rescheduled buprenorphine from a Schedule V drug to a Schedule III drug just before approval of Subutex and Suboxone. The ACSCN for buprenorphine is 9064, and being a Schedule III substance it does not have an annual manufacturing quota imposed by the DEA. The salt in use is the hydrochloride, which has a free base conversion ratio of 0.928. title: Buprenorphine text: in 1981. In 2012, 9.3 million prescriptions for the medication were written in the United States. Buprenorphine may also be used recreationally by injection or in the nose for the high it produces. Occasionally it is used recreationally instead of heroin. In the United States it is a Schedule III controlled substance. For the tablets the wholesale cost in the United States is between 0.86 and 1.32 per daily dose as of 2017. Its primary use is for the initial treatment of those with opioid addiction. It should only be started once symptoms of withdrawal have begun. For longer term